Findings

What do systematic reviews say?

387 questions · 404 findings · 22 reviews · Gut

Sort:Best matchNewest Highest certainty Download CSV

No studies found 96 · 23.8%GRADE not reported 3 · 0.7%Very low 108 · 26.7%Low 96 · 23.8%Moderate 69 · 17.1%High 32 · 7.9%

Viaskin milk patch vs placebo

Histological improvement (continuous) · active EoE pediatric patients

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 9 participants
Low

Viaskin milk patch vs placebo

Endoscopic improvement (dichotomous) · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Viaskin milk patch vs placebo

Endoscopic improvement (continuous) · active EoE pediatric patients

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 20 participants
Low

Viaskin milk patch vs placebo

Withdrawals due to adverse events · active EoE pediatric patients

Viaskin milk patch showed no clear difference in withdrawals due to adverse events at 44 weeks compared with placebo (low certainty).

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
RR 1.12 [0.05, 23.99]
1 study · 20 participants
Low

Leukotriene receptor antagonist vs placebo

Clinical improvement (dichotomous) · inactive EoE patients

It is very uncertain whether leukotriene receptor antagonist changes clinical improvement at 26 weeks (dichotomous) compared with placebo (very low certainty).

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
RR 1.68 [0.66, 4.28]
1 study · 41 participants
Very low

Oral 5‐ASA vs placebo

Failure to induce global or clinical remission · Patients with active mild to moderate ulcerative colitis

Oral 5‐ASA leads to lower failure to induce complete global or clinical remission compared with placebo (high certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.86 [0.82, 0.89]
11 studies · 2387 participants
High

Oral 5‐ASA vs SASP

Failure to induce endoscopic remission · Patients with active mild to moderate ulcerative colitis

The review found no eligible studies for this question.

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral 5‐ASA vs SASP

Failure to adhere to medication regimen · Patients with active mild to moderate ulcerative colitis

The review found no eligible studies for this question.

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral 5‐ASA vs SASP

Adverse events · Patients with active mild to moderate ulcerative colitis

Oral 5‐ASA probably leads to lower adverse events compared with SASP (moderate certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.48 [0.36, 0.63]
12 studies · 909 participants
Moderate

Oral 5‐ASA vs SASP

Serious adverse events · Patients with active mild to moderate ulcerative colitis

Oral 5‐ASA showed no clear difference in serious adverse events compared with SASP (low certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 1.36 [0.28, 6.52]
2 studies · 107 participants
Low

Oral 5‐ASA vs SASP

Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis

Oral 5‐ASA probably leads to lower withdrawal due to adverse events compared with SASP (moderate certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.4 [0.24, 0.68]
10 studies · 640 participants
Moderate

Once daily dosing vs conventional dosing

Failure to induce global or clinical remission · Patients with active mild to moderate ulcerative colitis

Once daily dosing showed no clear difference in failure to induce global or clinical remission compared with conventional dosing (high certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.99 [0.93, 1.06]
5 studies · 1761 participants
High

Once daily dosing vs conventional dosing

Failure to induce global or clinical improvement · Patients with active mild to moderate ulcerative colitis

Once daily dosing showed no clear difference in failure to induce global or clinical improvement compared with conventional dosing (moderate certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.74 [0.49, 1.1]
3 studies · 564 participants
Moderate

Once daily dosing vs conventional dosing

Failure to induce endoscopic remission · Patients with active mild to moderate ulcerative colitis

Once daily dosing showed no clear difference in failure to induce endoscopic remission compared with conventional dosing (high certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 1.02 [0.98, 1.07]
1 study · 817 participants
High

Once daily dosing vs conventional dosing

Failure to adhere to medication regimen · Patients with active mild to moderate ulcerative colitis

Once daily dosing showed no clear difference in failure to adhere to medication regimen compared with conventional dosing (low certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 1.36 [0.64, 2.86]
2 studies · 358 participants
Low

Once daily dosing vs conventional dosing

Adverse events · Patients with active mild to moderate ulcerative colitis

Once daily dosing showed no clear difference in adverse events compared with conventional dosing (moderate certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 1.02 [0.89, 1.18]
4 studies · 1586 participants
Moderate

Oral 5‐ASA vs placebo

Failure to induce global or clinical improvement · Patients with active mild to moderate ulcerative colitis

Oral 5‐ASA probably leads to lower failure to induce global or clinical improvement compared with placebo (moderate certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.68 [0.61, 0.75]
14 studies · 2256 participants
Moderate

Once daily dosing vs conventional dosing

Serious adverse events · Patients with active mild to moderate ulcerative colitis

Once daily dosing showed no clear difference in serious adverse events compared with conventional dosing (low certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 1.34 [0.68, 2.66]
4 studies · 1586 participants
Low

Once daily dosing vs conventional dosing

Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis

Once daily dosing showed no clear difference in withdrawal due to adverse events compared with conventional dosing (low certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.89 [0.54, 1.49]
5 studies · 1757 participants
Low

Oral 5‐ASA vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Failure to induce global or clinical remission · Patients with active mild to moderate ulcerative colitis

Oral 5‐ASA showed no clear difference in failure to induce global or clinical remission compared with comparator 5‐ASA (moderate certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.94 [0.86, 1.02]
11 studies · 1968 participants
Moderate